As pharmaceutical companies continue to face high attrition rates, rising development costs and increasingly complex clinical datasets, the industry is sea...
As biologics manufacturing operations become increasingly complex, biopharma companies are under growing pressure to improve efficiency, strengthen...
Sun Pharmaceutical Industries Limitedand Organon & Co. announced that they have entered into a definitive agreement under which Sun Pharma will acqui...
With Proposal #6, AIDS group urges shareholders to vote to request the company produce a report on the impact of extended patent exclusivities on patie...
Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative The...
OrganaBio, LLC ("OrganaBio"), a vertically integrated blood and cell products and services company delivering end-to-end solutions for cell and gene ther...
Marks AbbVie's largest-ever capital investment in a single campus since its inception Investment demonstrates continued progress a...
Marks the second major investment at the Slovenská Ľupča site in recent years Follows the group’s strategy to strengthen leading ...
The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and sev...
In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access an...
BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medi...
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio Silo Pharma, Inc. (Nasdaq: SILO...
© 2026 Biopharma Boardroom. All Rights Reserved.
